The U.S. clinical trials market is expanding steadily due to rising R&D investments, increasing drug development activities, and growing demand for advanced therapies, with the market projected to reach USD 59.17 billion by 2035 at a CAGR of 7.10%.

U.S. Clinical Trials Market Statical Scope

Due to strong biotech innovation, a rising chronic disease burden, high R & D investment, supportive FDA regulations increasing adoption of decentralized and digital trial technologies that improve efficiency and patient recruitments.

It is rapidly evolving with advanced technologies improving efficiency and accuracy. Artificial intelligence and machine learning are being used to speed up speech recruitments, predict outcomes, and optimize trial designs, decentralized, and hybrid trial models supported by wearable devices and mobile health apps enable real-time remote monitoring of patient cloud-based platforms and advanced data analytic s further enhance data management regulatory compliance and faster decision-making in research studies.

U.S. Clinical Trials Market Share, By Phase, 2025 (%)

• Phase I- The segment accounted for 16% of the total market share, because it involves only safety testing on a small group requiring fewer resources but high precision monitoring.
• Phase II- The segment accounted for 25% of the total market share, because it focuses on evaluating drug advocacy and optimal dosing in larger patient groups, requiring more extensive study design and monitoring.
• Phase III- The segment dominated the market with a 45% share, because it involves a large patient population confirmed treatment effectiveness monitors side effects and supports regulatory approval requirements.
• Phase IV- The segment accounted for 14% of the total market share, because it was conducted after approval to monitor long-term safety effectiveness and rare side effects in the real-world patient population.

U.S. Clinical Trials Market Share, By Study Design, 2025 (%)

• Interventional Trials- The segment dominated the market with a 70% share, because they directly test new treatments under control conditions, ensuring reliable efficacy and safety outcomes for regulatory approvals.
• Observational Trials- The segment accounted for 25% of the total market share, due to tracking real-world patient outcomes without interaction, providing valuable safety effectiveness and long-term disease progression data.
• Expanded Access Trials- The segment accounted for 5% of the total market share, because they provide treatment access to patients with serious conditions who have no alternative therapies after standard clinical trial options.

U.S. Clinical Trials Market Share, By Indication, 2025 (%)

• Autoimmune/Inflammation- The segment accounted for 10% of the total market share, due to rising cases of chronic immune disorders and continuous demand for novel targeted and biologic therapies.
• Pain Management- The segment accounted for 8% of the total market share, because of the high prevalence of chronic pain conditions and ongoing demand for safer non-opioid and effective therapeutic options.
• Oncology- The segment dominated the market with a 35% share, due to the high cancer burden, continuous innovation in targeted therapies and strong investment in advanced immune oncology research.

U.S. Clinical Trials Market Share, By Service, 2025 (%)

• Protocol Designing- The segment accounted for 10% of the total market share, because of a crucial early-stage service that ensures proper study structure regulatory comprehensive and reliable clinical outcomes.
• Site Identification- The segment accounted for 11% of the total market share, because efficient side selection and setup are critical for patient enrolment, protocol execution, the regulatory comprehensive and overall trial success.
• Patient Recruitment- The segment accounted for the market with a 20% share, due to enrolling suitable participants is the most challenging step requiring targeted outreach screening and retention strategies to ensure trial success.

U.S. Clinical Trials Market Share, By Sponsor, 2025 (%)

• Pharmaceutical & Biopharmaceutical Companies- The segment dominated the market with a 75% share, due to heavy R&D spending, strong drugs and continuous development of innovative therapies.
• Medical Device Companies- The segment accounted for 15% of the total market share, because they continuously test innovative devices, ensure safety and performance and meet strict FDA regulatory requirements.
• Others- The segment accounted for 10% of the total market share, because it includes academic institutes, government bodies, and small biotech firms conducting early-stage research studies.

Top Companies in the U.S. Clinical Trials Market

• IQVIA Inc.
• Parexel International Corporation
• Thermo Fisher Scientific Inc.
• ICON Plc.
• LabCorp
• Syneos Health
• Novotech
• Avance Clinical
• George Clinical
• Veritus Research
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Pfizer, Inc.
• Actinogen Medical
• Telix Pharmaceuticals
• PYC Therapeutics
• Neuren Pharmaceuticals
• AbbVie
• Merck Sharp & Dohme LLC

Segments Covered in the Report

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design

• Interventional Trials
• Observational Trials
• Expanded Access Trials

By Indication

• Autoimmune/Inflammation
• Pain Management
• Oncology
• CNS Conditions
• Diabetes
• Obesity
• Cardiovascular Diseases

By Service

• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Analytical Testing Services
• Clinical Trial Data Management Services
• Others

By Sponsor

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others